(Stroke. 1997;28:2039-2044.)
© 1997 American Heart Association, Inc.
Articles |
From the Department of Neurology, Tohoku University School of Medicine (T.H., K.A., H.S., Y.I.), and Department of Pharmaceutical Services, Tohoku Kouseinenkin Hospital (H.S.), Sendai, Japan.
Correspondence to K. Abe, MD, PhD, Department of Neurology, Tohoku University School of Medicine, 1-1 Seiryo-machi, Aoba-ku 980-77, Sendai, Japan. E-mail hayashi{at}neurol.med.tohoku.ac.jp
| Abstract |
|---|
|
|
|---|
Methods We used a transient middle cerebral artery (MCA) occlusion model. Northern blot analysis was performed to assess the chronological pattern of induction and the impact of length of ischemia on mRNA expression. Western blot analysis was performed to ensure the selective detection of immunoreactive VEGF with an antibody. Temporal, spatial, and cellular changes of immunohistochemical VEGF expression were compared with different periods of reperfusion from 1 hour to 7 days after transient MCA occlusion.
Results (1) Northern blot analysis revealed no detectable VEGF mRNA in the control brains. The mRNA became evident at 1 hour after reperfusion, peaked at 3 hours, and then decreased. The length of ischemia from 1 to 3 hours made no differences in the degree and temporal profile of the subsequent induction of VEGF mRNA. (2) Western blot analysis showed no band in the control brain, but two bands with molecular weights of 38 and 45 kD, corresponding to VEGF121 and VEGF165, were induced at 1 hour of reperfusion, peaked at 3 hours of reperfusion, and then decayed. (3) Neurons in the cerebral cortex of the MCA territory expressed VEGF at 1 hour after reperfusion with a peak at 3 hours and then diminished by 1 day. Pial cells of the MCA territory also expressed immunoreactive VEGF from 1 hour of reperfusion that was sustained until 3 to 7 days after reperfusion.
Conclusions Rapid induction of VEGF gene expression after transient MCA occlusion was demonstrated at both mRNA and protein levels. Cortical neurons and pial cells were the source of VEGF production in this model, but the temporal profiles of the induction between these cells were different. The early but dissociative induction of VEGF between neuronal and pial cells suggests different roles of the protein in their cells after transient MCA occlusion.
Key Words: angiogenesis cerebral ischemia rats
| Introduction |
|---|
|
|
|---|
It is well known that ischemic stroke causes active angiogenesis, particularly in the ischemic penumbra, which correlates with longer survival in humans.6 Therefore, it is speculated that VEGF plays an important role in the recovery of cerebral infarct. On the other hand, VEGF increases vascular permeability and is involved in the development of brain edema in patients with brain tumor.7 Thus, VEGF might also be harmful in cases of ischemic stroke by potentiating brain edema. Furthermore, VEGF has additional important roles in relaxing vascular smooth muscle cells,8 9 preventing apoptosis of endothelial cells,10 and inducing chemotaxis of monocytes under pathological conditions.4 When one considers these possible ambivalent effects of VEGF under pathological brain conditions such as cerebral ischemia, it is important to clarify how the VEGF gene is expressed in cerebral ischemia.
Previous studies revealed that hypoxia induces production of VEGF in cultured glial11 and endothelial12 13 cells. A recent study of permanent MCA occlusion in rats showed a late increase of VEGF protein in neurons, astrocytes, and macrophages with a peak at 1 day in the ischemic core and at 7 days in the penumbra.14 However, the effect of reperfusion on gene expression has not been reported. Unlike the case of permanent MCA occlusion, mild transient ischemia causes brain edema without development of cerebral necrosis.15 Thus, there may be a difference in the temporal profiles and the roles of VEGF between reperfused and permanent ischemic brains. We examined the induction of the VEGF gene at both mRNA and protein levels after mild transient MCA occlusion in rats. A rapid and dissociative induction of VEGF between neuronal and pial cells of the MCA territory was found after transient ischemia.
| Materials and Methods |
|---|
|
|
|---|
Sixty-seven male Wistar rats weighing 250 to 280 g were used. The rats were lightly anesthetized by inhalation of a 69%/30% (vol/vol) mixture of nitrous oxide/oxygen and 1% halothane during surgical preparation. A midline neck incision was made, and the right common carotid artery was exposed; inhalation of anesthetics was then stopped. When the animal began to regain consciousness, the right MCA was occluded by insertion of nylon thread through the common carotid artery, as described in our previous report.16 During these procedures, body temperature was monitored with a rectal probe and maintained at 37±0.3°C with the use of a heating pad. The restoration of CBF was accomplished by removal of the nylon thread under light anesthesia with diethyl ether. Between MCA occlusion and CBF restoration and after CBF restoration, the surgical incision was closed, and the animals were allowed free access to water and food at ambient temperature (21°C to 23°C).
The animals were divided into three experimental groups: group A, for investigation of mRNA induction (n=47); group B, for Western blot study (n=8); and group C, for immunohistochemical analysis (n=12).
Group A
To investigate how the length of ischemia influences the
degree and duration of mRNA induction for VEGF, 1, 2, or 3 hours of
ischemia was imposed on each animal. The animals were
decapitated under deep anesthesia with diethyl ether 1 or 3
hours or 1, 3, or 7 days after the restoration of CBF (n=3 in each time
point for each ischemic duration). Brain samples from two sham
control rats were obtained; these rats underwent a surgical procedure
until the carotid artery was exposed, but the MCA was not occluded.
Cerebral cortical samples of the right MCA territory were quickly
obtained and were immediately frozen in powdered dry ice. They were
temporarily kept at -70°C until the extraction of RNA.
Group B
The duration of ischemia was 90 minutes for these
animals. After 1 or 3 hours or 1 day of reperfusion, cerebral cortical
samples of the MCA territory were obtained (n=2) and kept as noted
above for group A. Sham controls samples (n=2) were also obtained.
Group C
For immunohistochemical analysis, the animals were
deeply anesthetized with pentobarbital (50 mg/kg IP).
Both deep cervical veins were cut at 1 or 3 hours or 1, 3, or 7 days of
reperfusion after 90 minutes of transient ischemia (n=2). The
brain was perfused with heparinized physiological
saline through the left cardiac ventricle at 110 mm Hg pressure
until colorless perfusion fluid was obtained from the cervical veins,
followed by an additional 200 mL of cold 4%
paraformaldehyde in PBS. The brain was removed and
stored in the same fixative at 4°C for 48 hours and embedded in
paraffin. Sham control animals (n=2) underwent the same procedure
except for MCA occlusion and reperfusion.
Northern Blot Analysis
Total RNAs were extracted from the cerebral cortical samples of
Group A animals by the guanidinium thiocyanate method. Northern
transfer and hybridization were essentially the same as described in
our previous report.15 In brief, 20 µg of total RNA was
electrophoresed in a 1.2% agarose gel containing 10% formaldehyde and
transferred overnight onto a nylon membrane (Hybond N, Amersham). RNA
was fixed with 1200 µJ ultraviolet (Stratalinker, Stratagene), and
then prehybridized. Signals for VEGF mRNA were detected with an
enhanced chemiluminescence method (direct nucleic acid labeling and
detection systems, Amersham) according to our previous
report.17 A cDNA clone of rat VEGF, a gift from Dr E.
Hashimoto (Fourth Department of Internal Medicine, School of Medicine,
University of Tokyo), was used as a probe. The specificity of this cDNA
had been established elsewhere.18 Then 0.6 kb of the
insert was released, and the insert DNA was labeled with horseradish
peroxidase and hybridized at 42°C for 20 hours in a hybridization
solution of the kit. After hybridization, the membrane was washed with
2xSSC (1x is 150 mmol/L NaCl, 15 mmol/L
trisodium citrate, pH 7.0), 0.4% SDS twice, 1xSSC with 0.2% SDS
once, and 20xSSC without SDS twice. Detection reagents in the kit were
added to the blots on the face carrying the RNA. The membrane was
exposed to an x-ray film for 30 minutes at room temperature and later
developed. Hybridization experiment was repeated with the use of a
tubulin DNA probe.14
Western Blot Analysis
The tissue samples were homogenized in a lysis
buffer (0.1 mol/L NaCl, 0.01 mol/L Tris-HCl, pH 7.5,
1 mmol/L EDTA, and 1 µg/mL aprotinin). Then the
homogenates were centrifuged at 7000g
for 15 minutes at 4°C, and the supernatents were used as protein
samples. Assays to determine the protein concentration of the
supernatants were subsequently performed by comparison with a known
concentration of bovine serum albumin with a kit (Micro BCA,
Pierce). SDS-gel electrophoresis was performed in a 10%
polyacrylamide gel under nonreducing conditions. Lysates
equivalent to 40 µg of protein from each samples were run on the gel
for 90 minutes at 20 mA, together with a size marker (rainbow colored
protein, Amersham). The electrophoresis running buffer contained
25 mmol/L Tris base, 250 mmol/L glycine, and
0.1% SDS. The proteins on the gel were subsequently transferred to the
polyvinylidene fluoride transfer membrane (Micron Separations
Inc) in a buffer containing 20% methanol, 39 mmol/L
glycine, 48 mmol/L Tris base, and 0.4% SDS.
After the transfer, the membrane was placed in 1% powdered milk in Tween PBS (PBS with 0.1% Tween 20) at 4°C for 16 hours to block nonspecific binding. Then it was washed with Tween PBS three times and incubated with mouse monoclonal antibody for VEGF (2E1, IBL) at 1:20 dilution in Tween PBS at 4°C for 20 hours. After it was washed with Tween PBS three times, the membrane was incubated with biotinylated anti-mouse IgG (Vectastain, PK-6102, Vector Laboratories) at 1:200 dilution in Tween PBS for 90 minutes at room temperature. It was washed with PBS for three times and incubated with biotin-avidin-peroxidase complex solution with the use of a kit (PK-6102, Vector Laboratories) for 60 minutes. The membrane was then developed with 3,3'-diaminobenzidine tetrahydrochloride (0.5 mg/mL in 50 mmol/L Tris-HCl, pH 7.5) in the presence of 0.02% H2O2. The membrane was then washed in distilled water and air dried. To ascertain specific binding of the antibody for the protein, another filter was stained in a similar way without the first antibody.
Immunohistochemical Analysis
Coronal sections at the caudate level were cut with 1 µm
thickness from the paraffinized samples of group C animals and mounted
on standard glass slides. Deparaffinization was achieved by treating
the specimens in xylene and subsequent ethanol, followed by a rinse in
PBS. After they were blocked with 10% normal horse serum for 2 hours,
the slides were washed in PBS and incubated with a mouse monoclonal
antibody against VEGF at 1:50 dilution in 10% normal horse serum and
0.3% Triton X-100 for 16 hours at 4°C. Endogenous
peroxidase activity was quenched by exposing the slides to 0.3%
H2O2 and 10% methanol for 20 minutes. The
slides were then washed and incubated for 3 hours with biotinylated
anti-mouse IgG at 1:200 dilution in PBS containing 0.018% normal horse
serum. Subsequently they were incubated with avidin-biotin-horseradish
peroxidase complex for 30 minutes and then developed with the use of
diaminobenzidine as a color substrate. The reaction was stopped by
washing the slides in distilled water. To ascertain specific binding of
the antibody for the protein, a set of brain sections was stained in a
similar way without the first antibody. The staining was categorized
into four grades, as follows: no staining (-), slight staining (±),
moderate staining (+), or dense staining (2+).
| Results |
|---|
|
|
|---|
|
Western Blot Analysis
Since the length of ischemia showed no essential
difference in the degree and temporal changes of VEGF gene expression,
the following studies were performed with constant duration of
ischemia for 90 minutes. As shown in Fig 2
, immunoreactive VEGF was barely
detectable in the control brain, but brain lysate at 1 hour of
reperfusion revealed two bands. These bands became more distinct in the
lysate at 3 hours of reperfusion and decreased at 1 day. The two bands
correspond to 38 and 45 kD, the former more strongly detected. These
bands correspond to VEGF121 and VEGF165,
respectively. A blot without the first antibody did not show any bands.
Duplicated samples in each time point showed reproducible results.
|
Immunohistochemical Analysis
Brain sections without the first antibody showed no staining. With
the antibody, immunoreactivity of VEGF was normally present in the
ependymal cells (data not shown), while there was no detectable
immunoreactive VEGF in neurons, glial cells, vascular
endothelial cells, or pial cells in control brains (Fig 3a
).
|
Our preliminary studies revealed that cerebral tissue necrosis occurred after 2 or 3 hours of ischemia, but no discernible tissue necrosis occurred under 90 minutes or 1 hour of transient ischemia. These results were essentially the same as those in our recent report.19
At 1 hour of reperfusion after transient MCA occlusion, immunoreactive
VEGF became detected in the cytoplasm of a part of neurons in the
cerebral cortex of the MCA territory (Fig 3b
, arrowheads).
Pyramidal neurons in the third to fifth layers of the
cerebral cortices were selectively stained. There was no expression in
neurons of caudate nucleus even within the MCA territory. At 3 hours
after reperfusion, the expression of VEGF in neurons of the MCA area
became more intense (Fig 3c
). The staining then greatly decreased at 1
day of reperfusion, with very slight staining in only a few neurons
(Fig 3d
, arrowhead). No more immunoreactive VEGF was found in neurons
at 3 and 7 days after reperfusion. No immunoreactive VEGF in vascular
endothelial or glial cells was documented at any stage
of reperfusion.
Pial cells of the MCA area showed no immunoreactive VEGF in control
brains (Fig 3e
, arrowhead). However, pial cells became stained from 1
hour after reperfusion, with a peak at 3 hours (Fig 3f
). Unlike the
temporal changes in cortical neurons, immunoreactivity in pial cells
was sustained until 3 to 7 days after reperfusion (Fig 3g
, arrowhead).
The expression of immunoreactive VEGF was restricted in the MCA
territory (Fig 3h
, left lower side from black arrowhead), in contrast
to the pia mater in the ipsilateral anterior cerebral artery area
showing a negative immunoreactivity for VEGF (Fig 3h
, right upper side
from black arrowhead). Sections at 1 hour of reperfusion showed
staining in neurons of the cerebral cortex in MCA territory and its
marginal zone (Fig 3h
, white arrowheads). The temporal profiles and the
staining properties of VEGF expression for each cell type of each
animal are reproducible and are summarized in the
Table
, illustrating the difference in
chronological sequence between neurons and pia mater.
|
| Discussion |
|---|
|
|
|---|
By immunohistochemical analysis, neurons in the cerebral cortex
and pial cells expressed immunoreactive VEGF after ischemic
insult (Fig 3
). Although previous studies demonstrated that VEGF gene
was induced in glial cells,24 glia-derived tumor
cells,25 26 cerebral endothelial
cells,12 13 and pericytes27 under hypoxic
conditions in vitro and in glial cells in permanent MCA occlusion in
vivo,14 glial cells and vascular
endothelial cells did not express the VEGF gene in this
experiment. Sensitivity for inducing the VEGF gene in neuronal, glial,
and pial cells may be different under conditions of
hypoxia/ischemia or ischemia/reperfusion. It is
intriguing that neurons in the third to fifth layers of cerebral cortex
selectively expressed immunoreactive VEGF (Fig 3a
through 3d). These
neurons are known to be selectively vulnerable to ischemic
insults.28 However, caudate neurons also vulnerable to
ischemia28 did not express the gene in the
present study. The reason for this dissociation is yet to be
clarified. This is the first report of VEGF gene expression in pial
cells. VEGF is a mitogen for endothelial
cells29 and also has the potential to increase vascular
permeability.30 31 Neovascularization usually occurs in
brain infarct,6 and the proliferation of
endothelial cells begins at 2 to 5 days after the
ischemic insult and continues for months.6 32
Therefore, the sustained expression of the VEGF gene in the pia mater
after ischemia (Fig 3e
through 3h) suggests its role in new
vessel formation in the affected area. On the other hand, the rapid and
transient induction of VEGF in neurons (Fig 3a
through 3d) seems to be
related to other functions, since transient induction of growth factor
is usually insufficient for new vessel formation.33 34 One
possibility is the protection of the vascular system against
ischemic insult, because VEGF protects capillary
endothelial cells from apoptotic cell
death.10 VEGF also relaxes vascular smooth muscle
cell8 9 and therefore might contribute to the protection
of brain tissue from ischemia.
In this experiment constitutive expression of VEGF in ependymal cells
did not affect the control level of mRNA (Fig 1
) because tissue samples
were obtained from the cerebral cortex of the MCA territory and did not
contain the above cells. On the other hand, it seems contradictory that
the pia mater expressed VEGF protein until 3 to 7 days of reperfusion
(Fig 3g
) without an evident signal of mRNA in Northern blot (Fig 1
).
This may be due to differences in sensitivity for detecting mRNA and
protein. The bulk of pia mater might be too small to detect VEGF mRNA
in Northern blot.
The effect of VEGF on increases in vascular permeability might worsen
brain edema caused by cerebral ischemia. However, brain edema
associated with mild cerebral ischemia is not mainly induced by
an increase in vascular permeability (vasogenic edema)
35 36 but rather is due to cellular damage (cytotoxic
edema).37 Although expression of VEGF and its ability to
increase vascular permeability were inhibited by
dexamethasone,38 dexamethasone was
not effective in reducing ischemic brain edema.37
Furthermore, the peak of brain edema in this model was 12 hours to 1
day,15 while the induction of VEGF gene was much more
earlier at 1 to 3 hours (Figs 1
and 2
). Thus, the early induction and
disappearance of VEGF gene in neurons may not be directly involved in
the brain edema formation in the present model.
Western blot analysis showed induction of two isoforms,
VEGF165 and VEGF121, in rat brain after
ischemia (Fig 2
). Since this antibody was raised against
full-length VEGF protein, the possibility that it does not detect
VEGF206 and VEGF189 even if these isoforms were
present cannot be excluded. However, a previous study suggested
that VEGF206 and VEGF189 were relatively rare
in rat brain.3 Furthermore, in a permanent MCA occlusion
model in rats, only VEGF165 and VEGF121 were
induced in the brain.14 It is therefore likely that only
two isoforms, VEGF165 and VEGF121, were induced
in the brain in this experiment. It has been reported that
VEGF206 and VEGF189, which bind to
proteoglycans, lack mitogenic activity for vascular
endothelial cells.5 It is therefore
probable that VEGF165 and VEGF121 play more
important roles in ischemic brains as diffusible isoforms of
VEGF.
In animal models of hindlimb ischemia39 40 and myocardial infarction,23 injection of VEGF was demonstrated to be therapeutically useful by potentiating angiogenesis and enhancing collateral blood flow. It has been reported that replication-deficient adenovirus as a vector of VEGF gene infected vascular endothelial cells and induced expression of VEGF.41 An injection of VEGF or gene therapy with VEGF might also be effective for reducing brain damage due to ischemic insults. In the present study, rapid expression with dissociative decrease of VEGF induction in different cell types was shown in MCA areas after transient ischemia. The different temporal profiles might be related to different roles in cerebral ischemia. Therefore, it is important to clarify the influence of VEGF on cerebral circulation, brain edema, and cerebral neovascularization under ischemic and/or reperfused conditions.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
Received December 23, 1996; revision received May 19, 1997; accepted June 3, 1997.
| References |
|---|
|
|
|---|
2.
Park JE, Chen HH, Winer J, Houck KA, Ferrara N.
Placenta growth factor. J Biol Chem. 1994;269:25646-25654.
3. Bacic M, Edwards NA, Merrill MJ. Differential expression of vascular endothelial growth factor (vascular permeability factor) forms in rat tissues. Growth Factors. 1995;12:11-15.[Medline] [Order article via Infotrieve]
4.
Simon M, Grone HJ, Johren O, Kulimer J, Plate KH,
Risau W, Fuchs E. Expression of vascular
endothelial growth factor and its receptors in human
renal ontogenesis and in adult kidney. Am J
Physiol. 1995;268:F240-F250.
5.
Monacci WT, Merrill MJ, Oldfield EH. Expression
of vascular permeability factor/vascular endothelial
growth factor in normal rat tissues. Am J
Physiol. 1993;264:C995-C1002.
6. Krupinski J, Kaluza J, Kumar P, Kumar S, Wang JM. Role of angiogenesis in patients with cerebral ischemic stroke. Stroke. 1994;25:1794-1798.[Abstract]
7. Strugar J, Rothbart D, Harrington W, Criscuolo R. Vascular permeability factor in brain metastasis: correlation with vasogenic brain edema and tumor angiogenesis. J Neurosurg. 1994;81:560-566.[Medline] [Order article via Infotrieve]
8.
Bauters C, Asahara T, Zheng LP, Takeshita S, Bunting
S, Ferrara N, Symes JF, Isner JM. Recovery of disturbed
endothelium-dependent flow in the collateral-perfused
rabbit ischemic hindlimb after administration of vascular
endothelial growth factor.
Circulation. 1995;91:2802-2809.
9.
Ku DD, Zaleski JK, Liu S, Brock TA. Vascular
endothelial growth factor induces EDRF-dependent
relaxation in coronary arteries. Am J
Physiol. 1993;265:H586-H592.
10. Alon T, Hemo I, Itin A, Pe`er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nature Med. 1995;1:1024-1028.[Medline] [Order article via Infotrieve]
11. Stein I, Neeman M, Shweiki D, Itin A, Keshet E. Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes. Mol Cell Biol. 1995;15:5363-5368.[Abstract]
12. Fischer S, Sharma HS, Karliczek GF, Schaper W. Expression of vascular permeability factor/vascular endothelial growth factor in pig cerebral microvascular endothelial cells and its upregulation by adenosine. Mol Brain Res. 1995;28:141-148.[Medline] [Order article via Infotrieve]
13. Ladoux A, Frelin C. Expression of vascular endothelial growth factors by cultured endothelial cells from brain vessels. Biochem Biophys Res Commun. 1993;194:799-803.[Medline] [Order article via Infotrieve]
14.
Kovacs Z, Ikezaki K, Samoto K, Inamura T, Fukui
M. VEGF and flt: expression time kinetics in rat brain
infarct. Stroke. 1996;27:1865-1873.
15. Abe k, Araki T, Kogure K. Recovery from edema and protein synthesis differs between the cortex and caudate following transient focal cerebral ischemia in rats. J Neurochem. 1988;51:1470-1476.[Medline] [Order article via Infotrieve]
16. Abe K, Kawagoe J, Araki T, Aoki M, Kogure K. Differential expression of heat shock protein 70 gene between the cortex and caudate after transient focal cerebral ischaemia in rats. Neurol Res. 1992;14:381-385.[Medline] [Order article via Infotrieve]
17. Fukudo S, Abe K, Hongo M, Utsumi A, Itoyama Y. Psychophysiological stress induces heat shock cognate protein (HSC) 70 mRNA in the cerebral cortex and stomach of rats. Brain Res. 995;675:98-102.
18.
Hashimoto E, Ogita T, Nakaoka T, Matsuoka R, Takao A,
Kira Y. Rapid induction of vascular endothelial
growth factor expression by transient ischemia in rat
heart. Am J Physiol. 1994;267:H1948-H1954.
19. Suzuki H, Abe K, Tojo S, Morooka S, Kimura K, Mizugaki M, Itoyama Y. Expression of P-selectin- and HSP72-like immunoreactivities in rat brain after transient middle cerebral artery occlusion. Brain Res. 1997;759:321-329.[Medline] [Order article via Infotrieve]
20.
Pierce EA, Avery RL, Foley ED, Aiello LP, Smith
LEH. Vascular endothelial growth factor/vascular
permeability factor expression in a mouse model of retinal
neovascularization. Proc Natl Acad Sci U S A. 1995;92:905-909.
21.
Levy AP, Levy NS, Loscalzo J, Calderone A, Takahashi N,
Yeo KT, Koren G, Colucci WS, Goldberg MA. Regulation of vascular
endothelial growth factor in cardiac myocytes.
Circ Res. 1995;76:758-766.
22. Shima DT, Deutsch U, D`Amore PA. Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability. FEBS Lett. 1995;370:203-208.[Medline] [Order article via Infotrieve]
23.
Banai S, Jaklitsch MT, Shou M, Lazarous DM, Scheinowitz
M, Biro S, Epstein SE, Unger EF. Angiogenic-induced enhancement
of collateral blood flow to ischemic myocardium by
vascular endothelial growth factor in dogs.
Circulation. 1994;89:2183-2189.
24. Ijichi A, Sakuma S, Tofilon PJ. Hypoxia-induced vascular endothelial growth factor expression in normal rat astrocyte cultures. Glia. 1995;14:87-93.[Medline] [Order article via Infotrieve]
25. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843-845.[Medline] [Order article via Infotrieve]
26. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potent tumor angiogenesis factor in human gliomas in vivo. Nature. 1992;359:845-848.[Medline] [Order article via Infotrieve]
27.
Nomura M, Yamagishi S, Harada S, Hayashi Y, Yamashima
T, Yamashita J, Yamamoto H. Possible participation of autocrine
and paracrine vascular endothelial growth factors in
hypoxia-induced proliferation of endothelial
cells and pericytes. J Biol Chem. 1995;270:28316-28324.
28. Pulsinelli WA, Brierley JB, Plum F. Temporal profile of neuronal damage in a model of transient forebrain ischemia. Ann Neurol. 1982:11;491-498.
29. Ferrara N, Henzel WJ. Pituitary follicular cells secret a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161:851-855.[Medline] [Order article via Infotrieve]
30.
Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder
J, Connolly DT. Vascular permeability factor, an
endothelial cell mitogen related to PDGF.
Science. 1989;246:1309-1342.
31.
Connolly DR, Olander JV, Heuvelman D, Nelson R, Monsell
R, Siegel N, Haymore BL, Leimgruber R, Feder J. Human vascular
permeability factor: isolation from U937 cells. J
Biol Chem. 1989;264:20017-20024.
32. Chen HH, Chien CH, Liu HM. Correlation between angiogenesis and basic fibroblast growth factor expression in experimental brain infarct. Stroke. 1994:25;1651-1657.
33.
Horrigan MCG, MacIsaac AI, Nicolini FA, Vince DG, Lee
P, Ellis SG, Topol EJ. Reduction in myocardial infarct size by
basic fibroblast growth factor after temporary coronary
occlusion in a canine model. Circulation. 1996;94:1927-1933.
34.
Isner JM, Walsh K, Symes J, Pieczek A, Takeshita S,
Lowry J, Rossow S, Rosenfield K, Weil L, Brogi E, Schainfeld R.
Arterial gene therapy for therapeutic angiogenesis in
patients with peripheral artery disease.
Circulation. 1995;91:2687-2692.
35.
Iannotti F, Hoff J. Ischemic brain edema
with and without reperfusion: an experimental study in gerbils.
Stroke. 1983;14:562-567.
36. Kuroiwa T, Ting P, Martinez H, Klatzo I. The biphasic opening of the blood-brain barrier to proteins following temporary middle cerebral artery occlusion. Acta Neuropathol (Berl). 1985;68:122-129.[Medline] [Order article via Infotrieve]
37. Fishman RA. Steroids in the treatment of brain edema. N Engl J Med. 1982;306:359-360.[Medline] [Order article via Infotrieve]
38. Bruce JN, Criscuolo GR, Merrill MJ, Moquin RR, Blacklock JB, Oldfield EH. Vascular permeability induced by protein product of malignant brain tumors: inhibition by dexamethasone. J Neurosurg. 1987;67:880-884.[Medline] [Order article via Infotrieve]
39. Asahara T, Bauters C, Zheng LP, Takeshita S, Bunting S, Ferrara N, Symes JF, Isner JM. Synergic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation. 1995;92(suppl):365-371.
40. Takeshita S, Pu LQ, Stein LA, Sniderman AD, Bunting S, Ferrara N, Isner JM, Symes JF. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation. 1994;90(pt 2):II-228-II-234.
41.
Muhlhauser J, Merrill MJ, Pili R, Maeda H, Bacic M,
Bewig B, Passaniti A, Edwards NA, Crystal RG, Capogrossi MC.
VEGF165 expressed by a replication-deficient recombinant
adenovirus vector induces angiogenesis in vivo. Circ
Res. 1995;77:1077-1086.
This article has been cited by other articles:
![]() |
C. K. Thompson and E. A. Brenowitz Neurogenesis in an Adult Avian Song Nucleus Is Reduced by Decreasing Caspase-Mediated Apoptosis J. Neurosci., April 8, 2009; 29(14): 4586 - 4591. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. P. Obrenovitch Molecular Physiology of Preconditioning-Induced Brain Tolerance to Ischemia Physiol Rev, January 1, 2008; 88(1): 211 - 247. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Baranova, L. F. Miranda, P. Pichiule, I. Dragatsis, R. S. Johnson, and J. C. Chavez Neuron-Specific Inactivation of the Hypoxia Inducible Factor 1{alpha} Increases Brain Injury in a Mouse Model of Transient Focal Cerebral Ischemia J. Neurosci., June 6, 2007; 27(23): 6320 - 6332. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Shimamura, G. Matchett, H. Yatsushige, J. W. Calvert, H. Ohkuma, and J. Zhang Inhibition of Integrin {alpha}v{beta}3 Ameliorates Focal Cerebral Ischemic Damage in the Rat Middle Cerebral Artery Occlusion Model Stroke, July 1, 2006; 37(7): 1902 - 1909. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Kimura, H. Nakase, R. Tamaki, and T. Sakaki Vascular Endothelial Growth Factor Antagonist Reduces Brain Edema Formation and Venous Infarction Stroke, June 1, 2005; 36(6): 1259 - 1263. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Ardelt, L. D. McCullough, K. S. Korach, M. M. Wang, D. H. Munzenmaier, and P. D. Hurn Estradiol Regulates Angiopoietin-1 mRNA Expression Through Estrogen Receptor-{alpha} in a Rodent Experimental Stroke Model Stroke, February 1, 2005; 36(2): 337 - 341. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Osuka, Y. Watanabe, N. Usuda, A. Nakazawa, M. Tokuda, and J. Yoshida Modification of Endothelial NO Synthase Through Protein Phosphorylation After Forebrain Cerebral Ischemia/Reperfusion Stroke, November 1, 2004; 35(11): 2582 - 2586. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Ferrara Vascular Endothelial Growth Factor: Basic Science and Clinical Progress Endocr. Rev., August 1, 2004; 25(4): 581 - 611. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Pleasure, P. Bannerman, J. Ara, M. Scarlato, and T. Itoh Prospects for Vascular Endothelial Growth Factor Neurotherapeutics Arch Neurol, May 1, 2002; 59(5): 692 - 694. [Full Text] [PDF] |
||||
![]() |
O. O. Ogunshola, A. Antic, M. J. Donoghue, S.-Y. Fan, H. Kim, W. B. Stewart, J. A. Madri, and L. R. Ment Paracrine and Autocrine Functions of Neuronal Vascular Endothelial Growth Factor (VEGF) in the Central Nervous System J. Biol. Chem., March 22, 2002; 277(13): 11410 - 11415. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-H. Lee, H. Avraham, S.-H. Lee, and S. Avraham Vascular Endothelial Growth Factor Modulates Neutrophil Transendothelial Migration via Up-regulation of Interleukin-8 in Human Brain Microvascular Endothelial Cells J. Biol. Chem., March 15, 2002; 277(12): 10445 - 10451. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-Q. Li, J. R. Ballinger, R. A. Nordal, Z.-F. Su, and C. S. Wong Hypoxia in Radiation-induced Blood-Spinal Cord Barrier Breakdown Cancer Res., April 1, 2001; 61(8): 3348 - 3354. [Abstract] [Full Text] |
||||
![]() |
H. Beck, T. Acker, C. Wiessner, P. R. Allegrini, and K. H. Plate Expression of Angiopoietin-1, Angiopoietin-2, and Tie Receptors after Middle Cerebral Artery Occlusion in the Rat Am. J. Pathol., November 1, 2000; 157(5): 1473 - 1483. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Jin, X. O. Mao, and D. A. Greenberg Vascular endothelial growth factor: Direct neuroprotective effect in in vitro ischemia PNAS, August 29, 2000; 97(18): 10242 - 10247. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Maloney, D. Wang, T. Duncan, N. Voelkel, and S. Ruoss Plasma Vascular Endothelial Growth Factor in Acute Mountain Sickness Chest, July 1, 2000; 118(1): 47 - 52. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J. H. Marti, M. Bernaudin, A. Bellail, H. Schoch, M. Euler, E. Petit, and W. Risau Hypoxia-Induced Vascular Endothelial Growth Factor Expression Precedes Neovascularization after Cerebral Ischemia Am. J. Pathol., March 1, 2000; 156(3): 965 - 976. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Rosmorduc, D. Wendum, C. Corpechot, B. Galy, N. Sebbagh, J. Raleigh, C. Housset, and R. Poupon Hepatocellular Hypoxia-Induced Vascular Endothelial Growth Factor Expression and Angiogenesis in Experimental Biliary Cirrhosis Am. J. Pathol., October 1, 1999; 155(4): 1065 - 1073. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. H. Marti and W. Risau Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors PNAS, December 22, 1998; 95(26): 15809 - 15814. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Yu, S. Tian, L. Metheny-Barlow, L.-J. Chew, A. J. Hayes, H. Pan, G.-L. Yu, and L.-Y. Li Modulation of Endothelial Cell Growth Arrest and Apoptosis by Vascular Endothelial Growth Inhibitor Circ. Res., December 7, 2001; 89(12): 1161 - 1167. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |